ClinicalTrials.gg
Not yet recruitingNCT07879807Updated Oct 19, 2026

Post-Stroke Apraxia, Motor Function, Balance, and Gait

An observational study in Stroke, Ideomotor Apraxia and Hemiplegia, sponsored by Izmir City Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Izmir City Hospital · Observational

Updated Oct 19, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
54
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The goal of this observational study is to examine whether ideomotor apraxia is associated with motor function, balance, walking performance, and independence in daily activities in adults with hemiplegia after stroke. Ideomotor apraxia is a condition in which a person has difficulty planning and correctly performing learned movements, despite understanding the instructions. It is common after stroke, particularly when the left side of the brain is affected.

The main questions this study aims to answer are:

  • Do participants with ideomotor apraxia have lower independence in daily activities, as measured by the motor subscale of the Functional Independence Measure (Motor FIM), than participants without apraxia?
  • Is the severity of ideomotor apraxia associated with upper limb motor function, balance, and walking performance?

Participants will attend one assessment session during routine follow-up at the Physical Medicine and Rehabilitation Clinic. They will undergo standardized clinical assessments of apraxia, upper limb motor function, balance, walking performance, and independence in daily activities. No treatment, medication, blood sampling, or imaging will be performed as part of this study.

Read the detailed description

This single-center, observational, cross-sectional study will investigate the association between ideomotor apraxia and functional outcomes in adults with post-stroke hemiplegia.

Ideomotor apraxia may interfere with the performance of purposeful movements and everyday tasks. Evaluating its relationship with motor impairment and functional performance may help clarify its relevance to rehabilitation assessment after stroke.

Participants will be evaluated during a single session at the Physical Medicine and Rehabilitation Clinic. Ideomotor apraxia will be assessed using the Test for Upper Limb Apraxia (TULIA). Upper limb motor impairment will be evaluated using the upper extremity section of the Fugl-Meyer Assessment. Additional standardized assessments will evaluate balance, walking performance, and independence in daily activities.

The primary analysis will compare Motor Functional Independence Measure (Motor FIM) scores between participants with and without ideomotor apraxia. Secondary analyses will examine associations between TULIA scores and measures of upper limb motor function, balance, and walking performance. Potential confounding factors, including demographic and stroke-related characteristics, will be considered in the analyses. Based on a previously reported effect size (Cohen's d = 1.06), with alpha = 0.05 and 90% power, a total of 54 participants will be enrolled, allowing for 10% data loss.

All study procedures are limited to clinical assessments and collection of relevant clinical information. Participation will not alter routine clinical care.

02

Conditions studied

  • Stroke
  • Ideomotor Apraxia
  • Hemiplegia

Keywords

  • Post-stroke rehabilitation
  • Upper limb motor function
  • Balance
  • Walking performance
  • Functional independence
  • Activities of daily living
  • Test for Upper Limb Apraxia
  • TULIA
  • Fugl-Meyer Assessment
  • Motor FIM
03

In context

Stroke

7,441 studies on the registry are indexed under Stroke; 2,012 are open to participants now.

This study's planned enrollment of 54 is below the median of 160 across 1,729 observational studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Izmir City Hospital is the lead sponsor of 25 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged 18 to 90 years with hemiplegia following ischemic or hemorrhagic stroke who attend the Physical Medicine and Rehabilitation Clinic at Izmir City Hospital, Türkiye. Patients meeting the eligibility criteria will be recruited consecutively during routine clinical visits. All study assessments will be completed during a single session.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 90 years.
  • Diagnosis of ischemic or hemorrhagic stroke with hemiplegia.
  • At least one month since stroke onset.
  • Provision of written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Severe aphasia preventing comprehension or performance of assessment instructions.
  • Mini-Mental State Examination score below 18 or severe cognitive impairment.
  • Severe unilateral spatial neglect.
  • Cerebellar stroke.
  • Another neurological disorder that may affect motor performance, including Parkinson disease, atypical parkinsonism, multiple sclerosis, or dementia.
  • Visual or hearing impairment preventing completion of the assessments.
  • Orthopedic disease, contracture, amputation, or recent surgery preventing upper or lower limb assessment.
  • Severe plantar flexor spasticity, defined as a Modified Ashworth Scale score of 3 or higher.
  • Fugl-Meyer upper extremity motor score below 20.
  • Inability to walk at least 10 meters with or without an assistive device.
  • Acute systemic illness or another medical condition preventing participation.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
54 participants (estimated)
Patient registry
No

Groups and cohorts

  • Stroke patients without ideomotor apraxia

    Other: Standardized clinical assessment

  • Stroke patients with ideomotor apraxia

    Other: Standardized clinical assessment

Interventions

  • OtherStandardized clinical assessment

    Single-session assessment including the Test for Upper Limb Apraxia (TULIA), Fugl-Meyer Assessment-Upper Extremity, Berg Balance Scale, Functional Ambulation Categories, 10-Meter Walk Test, and Functional Independence Measure. No treatment is administered.

06

What researchers measure

Primary outcomes

  1. Motor Functional Independence Measure (Motor FIM) Score

    The Motor FIM comprises 13 items assessing self-care, sphincter control, transfers, and locomotion. Scores range from 13 to 91, with higher scores indicating greater functional independence. Motor FIM scores will be compared between participants with and without ideomotor apraxia (defined by the Test for Upper Limb Apraxia \[TULIA\] cut-off), and their association with the TULIA total score will be examined.

    Time frame: At enrollment, during a single assessment session

Secondary outcomes

  1. Fugl-Meyer Assessment Upper Extremity Motor Score

    Upper limb motor impairment will be assessed using the upper extremity motor section of the Fugl-Meyer Assessment. Scores range from 0 to 66, with higher scores indicating better motor function. Its association with the TULIA total score will be examined.

    Time frame: At enrollment, during a single assessment session

  2. Functional Ambulation Categories Score

    Walking independence will be assessed using the Functional Ambulation Categories, scored from 0 to 5. Higher scores indicate greater walking independence and less need for assistance from another person. Its association with the TULIA total score will be examined.

    Time frame: At enrollment, during a single assessment session

  3. Comfortable Walking Speed on the 10-Meter Walk Test

    Comfortable walking speed will be assessed using the 10-Meter Walk Test and expressed in meters per second. Higher values indicate faster walking speed. Its association with the TULIA total score will be examined.

    Time frame: At enrollment, during a single assessment session

  4. Total Functional Independence Measure Score

    Overall functional independence will be assessed using the 18-item Functional Independence Measure, covering motor and cognitive domains. Total scores range from 18 to 126, with higher scores indicating greater independence. Its association with the TULIA total score will be examined.

    Time frame: At enrollment, during a single assessment session

  5. Berg Balance Scale Score

    Balance will be assessed using the Berg Balance Scale, comprising 14 items scored from 0 to 4. Total scores range from 0 to 56, with higher scores indicating better balance. Its association with the TULIA total score will be examined.

    Time frame: At enrollment, during a single assessment session

Other outcomes

  1. Test for Upper Limb Apraxia (TULIA) Total Score

    Ideomotor apraxia will be assessed through imitation and pantomime of meaningless, intransitive, and transitive gestures. Scores range from 0 to 240, with lower scores indicating more severe apraxia. Participants scoring below the established cut-off will be classified as having ideomotor apraxia.

    Time frame: At enrollment, during a single assessment session.

07

Study locations

1 site
  • Izmir City Hospital
    Izmir, İzmir 35540, Turkey (Türkiye)
08

References and documents

Publications

  • Cosar SNS, Ozen S, Selcuk ST, Yemisci OU. Does the presence of ideomotor apraxia in stroke patients adversely affect rehabilitation outcomes? A prospective study. Neurology Asia. 2020;25(4):459-465.
  • Vanbellingen T, Kersten B, Van Hemelrijk B, Van de Winckel A, Bertschi M, Muri R, De Weerdt W, Bohlhalter S. Comprehensive assessment of gesture production: a new test of upper limb apraxia (TULIA). Eur J Neurol. 2010 Jan;17(1):59-66. doi: 10.1111/j.1468-1331.2009.02741.x. Epub 2009 Jul 9. PubMed 19614961 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers to protect participant privacy and confidentiality. Study findings will be reported in aggregate form through scientific publications and presentations.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2026
First posted
Oct 19, 2026
StartEst.
Oct 15, 2026
Primary completionEst.
Oct 15, 2027
CompletionEst.
Oct 15, 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07879807
Lead sponsor
Izmir City Hospital
Responsible party
Sponsor
First posted
Oct 19, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Oct 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Aylin Dikici, MD
Contact
aylinkaraman401@hotmail.com
+90 506 484 34 42
Aylin Dikici, MD
principal investigator · University of Health Sciences, Izmir City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion